CTOs on the Move

PharmaLinkFHI Inc

www.pharmalinkfhi.com

 
PharmaLinkFHI (PharmaLink) is the first full-service Clinical Research Organization (CRO) to integrate clinical and technological expertise in managing Phase I-IV clinical trials online in real time. Biopharmaceutical and medical device organizations
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Consumer Healthcare Products Association

Founded in 1881, the Consumer Healthcare Products Association (CHPA) is the national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system $6-$7, contributing a total of $102 billion in savings each year. CHPA is committed to promoting the increasingly vital role of OTC medicines and dietary supplements in America`s healthcare system through science, education, and advocacy.

ChemCon America

ChemCon America is a Lake Mary, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

JOM Pharmaceutical Services

JOM Pharmaceutical Services is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vallon Pharmaceuticals

Vallon is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. $VLON

Silence Therapeutics

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.